These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17184525)

  • 1. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.
    Krypuy M; Newnham GM; Thomas DM; Conron M; Dobrovic A
    BMC Cancer; 2006 Dec; 6():295. PubMed ID: 17184525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
    Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
    BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
    Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
    J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
    BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases.
    Wu J; Zhou Y; Zhang CY; Song BB; Wang BL; Pan BS; Lou WH; Guo W
    Asian Pac J Cancer Prev; 2014; 15(24):10647-52. PubMed ID: 25605154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unlabeled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in pancreatic adenocarcinoma tissues.
    Guo W; Zhang C; Wu J; Song B; Wang B; Zhou Y; Zhou J; Shen M; Zhang C; Zhang X; Guan M; Pan B
    Clin Chem Lab Med; 2012 Jan; 50(6):1035-40. PubMed ID: 22706243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
    Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.
    Do H; Dobrovic A
    Mol Cancer; 2009 Oct; 8():82. PubMed ID: 19811662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different screening methods for the KRAS mutation in colorectal cancer.
    Er TK; Chang YS; Yeh KT; Chang TJ; Chang JG
    Clin Lab; 2010; 56(5-6):175-86. PubMed ID: 20575464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis.
    Song C; Milbury CA; Li J; Liu P; Zhao M; Makrigiorgos GM
    Diagn Mol Pathol; 2011 Jun; 20(2):81-9. PubMed ID: 21532494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Snapback primer mediated clamping PCR for detection of EGFR and KRAS mutations in NSCLC patients by high resolution melting analysis.
    Sun H; Yang Y; Yang L; Su B; Jiang G; Fei K; Lu D
    Biomed Res Int; 2014; 2014():407537. PubMed ID: 24883309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential high-resolution melting analysis for the detection of K-ras codons 12 and 13 mutations in pancreatic cancer.
    Zhang C; Guo W; Wu J; Song B; Zhang C; Dai Q; Pan B; Ji Y; Guo J
    Pancreas; 2011 Nov; 40(8):1283-8. PubMed ID: 21989023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.
    Chretien AS; Harlé A; Meyer-Lefebvre M; Rouyer M; Husson M; Ramacci C; Harter V; Genin P; Leroux A; Merlin JL
    Cancer Med; 2013 Feb; 2(1):11-20. PubMed ID: 24133623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.